{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-21-000197","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.136381+00:00","generated_at":"2026-06-29T18:23:59.492764+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M","bullets":["Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.","DecisionDx-Melanoma test reports up 70% YoY to 5,128; total dermatology test volume 6,539.","Full-year 2021 revenue guidance raised to $89-93M from prior $80-83M.","Acquired Myriad myPath Laboratory for $33M in May, adding myPath Melanoma test.","Cash at $368M; operating cash flow -$6.4M due to acquisition and Medicare advance recoupment."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-21-000197","json":"https://secwatch.observer/filing/0001447362-21-000197.json","markdown":"https://secwatch.observer/filing/0001447362-21-000197.md","text":"https://secwatch.observer/filing/0001447362-21-000197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736221000197/0001447362-21-000197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736221000197/cstl-20210809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:23:59.492764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}